The initial-public-offering market is gearing up for the arrival of the Birkenstock deal this week, with the iconic German sandal maker expected to price its stock on Tuesday for a Wednesday debut.
Birkenstock IPO Details
Birkenstock (ticker: BIRK) is planning to offer 32.3 million shares priced at $44 to $49 each. The company aims to raise $1.58 billion at the top end of the range, valuing the company at $9.2 billion.
Listing and Underwriters
The company has applied to be listed on the New York Stock Exchange under the ticker BIRK. A team of 22 banks, led by Goldman Sachs, JPMorgan, and Morgan Stanley, will act as underwriters for the IPO. Additionally, underwriters have the option to purchase up to 4.8 million more shares from the selling shareholders to cover overallotments.
Birkenstock's Strengths
“Birkenstock is pitching a combination of profitability and growth, along with widespread brand recognition,” said Renaissance Capital Founder and CEO Bill Smith. Despite recent weak aftermarket trading from large IPOs, Birkenstock's robust fundamentals suggest a promising debut.
It's worth noting that even before the current hostilities in Israel broke out, the market had witnessed three key deals losing some of their allure shortly after their debuts.
Chip Maker Arm Holdings, Digital Marketing Company Klaviyo, and Instacart Experience Strong First-Day Trading
Chip maker Arm Holdings Ltd. (ARM) experienced significant gains on its first day of trade, as did digital marketing company Klaviyo (KVYO) and Instacart, trading as Maplebear Inc. (CART). However, these companies saw a decrease in their stock prices in the following sessions. On Monday, Instacart's stock price was quoted at $24.10, which was well below its IPO issue price of $30.
Instacart Faces Uncertain Market Sentiment
Related: Instacart shares slump to their IPO price as investors have second thoughts
Instacart, a grocery delivery company, saw its shares slump to its IPO price of $30, indicating that some investors may be having second thoughts about the company's prospects.
Introduction of Gamer Pakistan Inc. to the U.S. Exchange
Gamer Pakistan Inc. (GPAK), a small pre-revenue company, faced a 29% decrease in its stock price on its first day of trade. The company priced its initial public offering (IPO) at $4 a share, which was at the lower end of the $4 to $5 range. However, it faced delays in trading as it worked through issues with Nasdaq. Notably, this makes Gamer Pakistan Inc. the first company from Pakistan to list on a U.S. exchange.
Financial Overview of Gamer Pakistan Inc.
Gamer Pakistan Inc. raised $6.8 million through its IPO by selling 1.7 million shares. With a total of 25.6 million shares outstanding, the company had a valuation of $102.4 million at the IPO price. The stock is now trading on Nasdaq under the ticker GPAK.
Company Profile and Financial Concerns
“We are a development-stage interactive esports event promotion and product marketing company, founded in November 2021,” the company stated in its filing documents with the Securities and Exchange Commission. However, Auditor Mercurius & Associates LLP expressed concerns about the company's pre-revenue deficit and raised doubts about its ability to continue as a going concern. It's worth noting that such language is typical in IPO filings for companies that are pre-revenue, including pre-clinical biotechnology companies.
Market Performance
As of the year-to-date figures, the Renaissance IPO ETF (IPO) has gained 28%, while the S&P 500 (SPX) has gained 13%.
Read next: Esports company Gamer Pakistan stock becomes the first entity from that country to list on a U.S. exchange
Our Latest News
Ascential Announces Sale of Two Businesses and Return to Shareholders
Ascential reveals plan to sell its digital commerce and product design businesses, with a total value of £1.4 billion, and return £850 million to shareholders t...
The Symbolism of Conflict: Hamas Attacks Israel
This article discusses the recent Hamas attack on Israel and its symbolism, as well as its impact on oil prices and global reliance on OPEC oil. It also explore...
New Data Released from CureVac COVID-19 Vaccine Trial
CureVac's COVID-19 vaccine shows positive results in trial, competing with Moderna and Pfizer. Shares rise 3%.